Fbx2-E3 ligase mediated degradation of BACE1 attenuates Alzheimer amyloidosis and improve synaptic function

Bing Gong,Fei Chen,Yong Pan,Isabel Arrieta-Cruz,Yukiko Yoshida,Vahram Haroutunian,Giulio Maria Pasinetti
DOI: https://doi.org/10.1016/j.jalz.2010.05.1961
2010-01-01
Alzheimer s & Dementia
Abstract:Progressive deposition of insoluble amyloid beta protein (Aβ1-42) in the brain is a neuropathological hallmark of Alzheimer's Disease (AD). BACE1 (β-site APP cleaving enzyme) is a rate-limiting enzyme in β-amyloid (Aβ) peptide production and involves the pathogenesis of Alzheimer's disease (AD). The metabolic process of BACE1 is tightly regulated in a complex manner, including endocytosis, lysosome targeting, and ubiquitin-proteasome system (UPS)-regulated degradation. The UPS, a major protein quality control system, is dysregulated in many neurodegenerative diseases, including AD. The deficits of the UPS have been reported linked with an increase of BACE1 protein levels and leading to increased APP processing and Aβ1-42 accumulation in AD brains in which the molecular mechanisms are largely unknown. Here we report that SCFFbx2 acts as a specific E3 ligase interacts with BACE1 and promotes BACE1 ubiquitination and degradation, and attenuate Aβ1-42 neuropathology in an AD animal model. Co-immunoprecipitation (CO-IP) in Neuro-2A cells stably expressing BACE1 and co-transfected with full length Fbx2 and variants (in vitro) and in AD brain tissues (in vivo). The effects of Fbx2 on BACE1 protein levels and degradation kinetics were assessed by Cycloheximide (CHX) chase analysis. Adenoviral-Fbx2 stereotaxic hippocampal injection injections in Tg CRND8 brains [over-expressing APPswe (K670N and M671L) and the Indiana (V717F)] to study the effects of Fbx2 on BACE1 level, Aβ1-42 production and synaptic function in this AD mouse model. (1) Fbx2-E3 ligase binds with BACE1 via sugar-binding domain (SBD). (2) SBD (W280), but not K281 or Y279 in hydrophobic pocket of Fbx2 protein is essential for the interaction with BACE1. (3) Fbx2 and BACE1 co-localized mainly in early endosomal compartment. (4) CHX chase experiments show that expression of Fbx2 markedly reduces the BACE1 protein levels and Aβ production. (5) More importantly, exogenous adenoviral Fbx2 expression in the brain of TgCRND8 mice significantly decreases BACE1 protein content and activity coincidental with reduction of Aβ level and rescue of synaptic deficits. Our studies for the first time suggest that Fbx2 specially recognize BACE1 and promotes BACE1 degradation by UPS. Thus enhancing Fbx2 levels in the brain may represent a novel strategy for treatment of AD.
What problem does this paper attempt to address?